A Biobank of Colorectal Cancer Patient-Derived Xenografts.

Cancers (2020-08-23)
Suad M Abdirahman, Michael Christie, Adele Preaudet, Marie C U Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M Sieber, Tracy L Putoczki

Colorectal cancer (CRC) is a challenging disease, with a high mortality rate and limited effective treatment options, particularly for late-stage disease. Patient-derived xenografts (PDXs) have emerged as an informative, renewable experimental resource to model CRC architecture and biology. Here, we describe the generation of a biobank of CRC PDXs from stage I to stage IV patients. We demonstrate that PDXs within our biobank recapitulate the histopathological and mutation features of the original patient tumor. In addition, we demonstrate the utility of this resource in pre-clinical chemotherapy and targeted treatment studies, highlighting the translational potential of PDX models in the identification of new therapies that will improve the overall survival of CRC patients.

Product Number
Product Description

5-Fluorouracil, ≥99% (HPLC), powder
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Fetal Bovine Serum, Australia origin, suitable for, USDA approved, sterile-filtered, suitable for cell culture, suitable for hybridoma
Carprofen, ≥97% (HPLC)